1.2. Pediatrics
Safety and efficacy of enoxaparin for use in children younger than 18 years of age have not been established1-3. Dalteparin is FDA approved to treat VTE to reduce VTE recurrence in pediatric patients greater than or equal to 1 month of age1,2,4. Dalteparin pediatric dosages are summarized in Table 2. Dosages exceeding these recommendations will be reviewed.
Treatment Indication | Drug Name | Maximum Recommended Dosage |
---|---|---|
Venous thromboembolism treatment | Dalteparin |
|